Hybrid amide derivatives of amphotericin b
AssigneeThe Board of Trustees of the University of Illinois
InventorsMartin D. Burke, Arun Maji
Life of this patent
Estimating the term…
Abstract
Disclosed are C16 amide derivatives of C2′-epi-amphotericin B (C2′epiAmB) and salts thereof, characterized by improved clinical efficacy with reduced toxicity compared to AmB. Also disclosed are pharmaceutical compositions, comprising any of the disclosed compounds or salts thereof, as well as methods of treatment and therapeutic uses of the same.
Claims16
A method of treating a fungal infection in a subject in need thereof, comprising administering to the subject a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof, wherein the fungal infection is caused by at least one Aspergillus species.
A method of making a compound of formula I:
- comprising the step of:
- reacting a compound of formula IA:
- with 2-amino-1,3-propanediol in the presence of a base, under conditions sufficient to form a compound of formula 1.
A method of reducing fungal burden in a subject in need thereof, comprising administering to the subject a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.